One-Hour Plasma Glucose Identifies Insulin Resistance and β-Cell Dysfunction in Individuals With Normal Glucose Tolerance: Cross-sectional data from the Relationship between Insulin Sensitivity and Cardiovascular Risk (RISC) study by Manco, Melania et al.
One-Hour Plasma Glucose Identiﬁes Insulin
Resistance and -Cell Dysfunction in
Individuals With Normal Glucose Tolerance
Cross-sectional data from the Relationship between Insulin Sensitivity and
Cardiovascular Risk (RISC) study
MELANIA MANCO, MD, PHD
1
SIMONA PANUNZI, PHD
2
DAVID P. MACFARLANE, MBCHB
3
ALAIN GOLAY, MD
4
OLLE MELANDER, MD, PHD
5
THOMAS KONRAD, MD
6
JOHN R. PETRIE, MBCHB, PHD
7
GELTRUDE MINGRONE MD, PHD
8
ON BEHALF OF THE RELATIONSHIP BETWEEN
INSULIN SENSITIVITY AND
CARDIOVASCULAR RISK (RISC)
CONSORTIUM
OBJECTIVE — Some individuals with normal glucose tolerance (NGT) exhibit a 1-h excur-
sion of plasma glucose during oral glucose tolerance testing as high as that of individuals with
impaired glucose tolerance (IGT). The aim of this study was to characterize their metabolic
phenotype.
RESEARCH DESIGN AND METHODS — A total of 1,205 healthy volunteers (aged
29–61 years) underwent assessment of 1) oral glucose tolerance and 2) insulin sensitivity
(standardized euglycemic-hyperinsulinemic clamp), as part of the Relationship between Insulin
Sensitivity and Cardiovascular Risk (RISC) study.
RESULTS — One-hour plasma glucose correlated better than 2-h plasma glucose with
total insulin secretion (r  0.43), -cell glucose sensitivity (r  0.46), and -cell rate
sensitivity (r  0.18). Receiver operating characteristic analysis identiﬁed 8.95 mmol/l as
the best cutoff value for prediction of IGT from 1-h plasma glucose (sensitivity 77% and
speciﬁcity 80%). Participants with NGT with 1-h plasma glucose 8.95 mmol/l had larger
waist circumference, higher BMI, lower insulin sensitivity, higher fasting glucose, and
higherinsulinsecretionthantheircounterpartswith1-hplasmaglucose8.95mmol/l(P 
0.001 for all comparisons). Moreover, they exhibited lower -cell glucose sensitivity (P 
0.001), -cell rate sensitivity (P  0.001), and potentiation factor (P  0.026). When
compared with conventionally deﬁned IGT, they were not different in waist circumference
and BMI, hepatic insulin extraction, -cell glucose sensitivity, -cell rate sensitivity, and
potentiation factor but did have greater insulin sensitivity along with reduced basal (P 
0.001) and total insulin secretion (P  0.002).
CONCLUSIONS — Higher values of 1-h plasma glucose may identify an intermediate con-
dition between NGT and IGT characterized by greater insulin resistance, reduced -cell glucose
sensitivity, and reduced -cell rate sensitivity.
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I
mpaired glucose tolerance (IGT) and
impaired fasting glucose (IFG) are
states of carbohydrate metabolism in-
termediate between normal glucose toler-
ance (NGT) and type 2 diabetes, which
represent two partially overlapping con-
ditions with distinct metabolic charac-
teristics (1,2). In IFG, there is marked
hepatic insulin resistance with near-
normal muscle insulin sensitivity,
whereas this pattern is reversed in IGT
(2). Although both conditions are charac-
terized by reduced early-phase insulin se-
cretion, there is an additional impairment
of late-phase insulin secretion in IGT. Ac-
cordingly, individuals with IGT have a
rapid early (30 min) rise in plasma glu-
cose during an oral glucose tolerance test
(OGTT) which continues to rise until 60
min (1-h plasma glucose) and thereafter
remains 7.8 mmol/l (140 mg/dl) at 120
min (2-h plasma glucose).
As longitudinal studies have demon-
strated that 40% of patients who develop
type2diabetesafter10yearshaveNGTat
baseline (1), there may be additional in-
formation beyond conventional IFG/IGT
categoriesthatmaybetterdiscriminatefu-
ture progression to type 2 diabetes (3).
We have noted a subset of individuals
with NGT who have early glucose excur-
sions during an OGTT as high as those
observed in individuals with IGT. How-
ever, because plasma glucose concentra-
tions decline adequately by 2 h, due to
preservation of late-phase insulin secre-
tion, these individuals do not have, by
current deﬁnitions, any form of disor-
dered carbohydrate metabolism (4). Data
from the San Antonio Study have shown
that -cell glucose sensitivity and insulin
sensitivity contribute to values of 2-h
plasma glucose independently of each
other (5); thus, we hypothesized that in-
dividuals with NGT with 1-h plasma glu-
cose levels as high as in those with IGT
might represent an intermediate pheno-
type of abnormal carbohydrate metabo-
lism with either impaired insulin
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who are potentially at increased risk of
progression to type 2 diabetes.
To investigate this hypothesis we an-
alyzed cross-sectional data from the Eu-
ropean Relationship between Insulin
Sensitivity and Cardiovascular Risk
(RISC) study (6), examining the meta-
bolic phenotype of individuals with NGT
who had high 1-h plasma glucose excur-
sions.Weaimedtoidentifyanewglucose
tolerance subgroup who might beneﬁt
fromtargetedlifestyleadviceand/orphar-
macological intervention.
RESEARCH DESIGN AND
METHODS— The RISC study is a pro-
spective (3- and 10-year follow-up), obser-
vational, cohort study. Primary objectives
include 1) establishing whether insulin re-
sistance predicts deterioration of cardiovas-
cular risk markers, diabetes, obesity,
atherosclerosis, and cardiovascular disease
and2)developingmethodsbasedonmath-
ematical modeling to identify insulin-
resistant participants in clinical practice.
Healthy adults, aged 29–61, with no
history of diabetes, hypertension, or hy-
perlipidemia were recruited from 18 cen-
ters across Europe between 2002 and
2004. Speciﬁc inclusion and exclusion
criteriaarereportedelsewhere(6).Partic-
ipants gave written informed consent and
local ethics committee approval was ob-
tainedineachcenter.Everyvolunteerhad
a clinical examination, including body
composition estimated by bioimpedance
(TBF-300 body composition analyzer;
Tanita,Hoofddorp,theNetherlands),and
underwenta75-gOGTTandeuglycemic-
hyperinsulinemic clamp (EHC).
OGTT
After an overnight fast, a 75-g OGTT was
performedinthemorning,withsampling
atbaselineandat30,60,90,and120min
after glucose ingestion, with measure-
ment of glucose, insulin, and C-peptide.
DatafromtheOGTTwereusedforassess-
ment of -cell function and calculation of
mean hepatic insulin extraction
[(HIEOGTT  1  (clearance from the
clamp)/(endogenousclearanceduringthe
OGTT)].
EHC
One to 3 weeks after the OGTT, an EHC
was performed in all participants. Exoge-
nousinsulinwasadministeredasprimed-
continuous infusion at a rate of 240 pmol  
min
1   m
2, with a simultaneous vari-
able infusion of 20% dextrose adjusted
every 5 min to maintain plasma glucose
within 0.8 mmol/l (15%) of the target
glucose level (4.5–5.5 mmol/l). The
clampprocedurewasstandardizedacross
centers (6). An initial fasting blood sam-
ple and two samples during the last 40
min of the clamp were taken for measure-
ment of glucose, insulin, and C-peptide
concentrations. Insulin sensitivity was as-
sessed as the mean glucose infusion rate
over the last 40 min of the clamp, cor-
rected for mean plasma insulin levels
achieved during the same period (M/I, in
micromoles per minute   per kilogram of
free fat mass [FFM] per nanomoles per
liter). The peripheral clearance of insulin
during the clamp (liters per minute per
meter squared) was computed as follows:
Iclclamp  (240 pmol   min
1   m
2 insu-
lin infusion)/(steady-state insulin).
Assessment of -cell function
-Cell function was assessed from the
OGTT using a well-validated model that
describes the relationship between insu-
lin secretion and glucose concentration
(7,8). The model expresses insulin secre-
tion (in picomoles per minute per meter)
asthesumoftwocomponents.Theﬁrstis
-cell glucose sensitivity, which repre-
sents the dependence of insulin secretion
on absolute glucose concentration at any
time point during the OGTT through a
dose-response function relating the two
variables (expressed as the mean slope of
dose response over the observed glucose
range). This dose response is modulated
by a potentiation factor, which accounts
for higher insulin secretion on the de-
scending phase of OGTT hyperglycemia
thanatthesameglucoseconcentrationon
the ascending phase. The potentiation
factor is a positive function of time and is
constrained to average unity during the
experiment (9). The second insulin secre-
tion component represents the depen-
dence of insulin secretion on the rate of
change of glucose concentration. This
component is determined by a single pa-
rameter,denotedasratesensitivity,andis
related to early insulin release (9).
The model parameters were esti-
mated from glucose and C-peptide con-
centrations by regularized least squares
(7,8). Insulin secretion rates were calcu-
lated from the model every 5 min. The
integral of insulin secretion during the
2-h OGTT was denoted as total insulin
output.
Analytical methods
Local laboratory data were used for study
inclusion criteria. Blood collected was
storedat20°Candcentrallyanalyzedin
Odense, Denmark. Plasma glucose was
measured by the glucose oxidase tech-
nique (Cobas Integra; Roche, Basel, Swit-
zerland); serum insulin and C-peptide
were measured by a speciﬁc time-
resolved ﬂuoroimmunoassay (Au-
toDELFIA insulin kit; Wallac Oy, Turku,
Finland).
Statistical analysis
Continuous data are reported as mean 
SD, with categorical data as counts and
percentages. 
2 tests was used for com-
paring association between categorical
variables, and ANOVA was performed for
comparison among groups and for re-
peatedmeasures.Stepwiselogisticregres-
sion analysis was used to predict insulin
resistance from age, sex, 1-h plasma glu-
cose, 2-h plasma glucose, BMI, and waist
circumference. Receiver operating char-
acteristic curve analysis was used to eval-
uate speciﬁcity and sensitivity of plasma
glucose at 60 min to identify individuals
with IGT. Odds ratios (ORs) were com-
putedtoestimateriskofinsulinresistance
orimpairedinsulinsecretionaccordingto
1-h plasma glucose levels.
Insulin sensitivity was expressed as
the natural logarithm of the M/I ratio. In-
sulin resistance was deﬁned categorically
as the lowest decile of the ln(M/I) as done
previously (10) in those participants who
were nonobese (BMI 25 kg/m
2), with
normal values of fasting and 2-h glucose
and no family history for diabetes. Indi-
viduals satisfying these criteria served as
the control subjects. Categories of “insu-
lin hypersecretion” and “insulin hypose-
cretion”weredeﬁnedastheupperandthe
lowest deciles of insulin secretion (basal
or total), in those control subjects pre-
senting with insulin sensitivity between
the lowest and the upper deciles of
ln(M/I). The same approach (upper and
lower deciles) was also used for hepatic
insulin extraction, peripheral insulin
clearance, -cell glucose sensitivity, and
ratesensitivity.IFGandIGTweredeﬁned
according to the criteria of the American
Diabetes Association (4).
P  0.05 was considered as statisti-
cally signiﬁcant. Data analysis was per-
formed with SPSS statistical software
(version 12.0; SPSS, Chicago, IL).
RESULTS— After we excluded indi-
viduals from the initial sample (n 
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diabetes (n  30), or with missing OGTT
and clamp data (n  309), 1,205 (56.1%
women) individuals (aged 44  8 years)
withcompleteEHCdatawereincludedin
the analysis. Of these, 509 participants
(42.2%) were overweight or obese (BMI
25 kg/m
2) and 105 met the criteria for
IGT (8.7%).
Prevalence of insulin resistance
Thirty-two overweight/obese participants
(mean BMI 28.45  3.04 kg/m
2) were
insulin resistant [ln(M/I) 4.48). Among
these insulin-resistant individuals, 41%
had total cholesterol 5.2 mmol/l (P 
0.001, in comparison with insulin-
sensitive individuals), 42% had LDL cho-
lesterol 3.3 mmol/l (P  0.002), 37%
had HDL cholesterol 1.03 mmol/l
(men) or 1.3 (women) (P  0.001),
24% had circulating triglycerides 1.7
mmol/l(P0.001),and42%hadawaist
circumference 102 cm (men) or 88
cm (women) (P  0.001).
Prevalence of insulin hyper- and
hyposecretion
There were 341 (28.3%) “hypersecretors”
and 80 (6.6%) “hyposecretors,” deﬁned
as 86.42 and 38.13 pmol   min
1  
m
2, respectively (equivalent ﬁgures
were 43.12 and 3.05%, respectively, for
overweight/obese participants). For total
insulin secretion, there were 230 (19.1%)
hypersecretors and 110 (9.1%) hypose-
cretors, deﬁned as 51.97 and 25.21
nmol   m
2 (equivalent ﬁgures were 26.1
and 7.1% for overweight/obese
participants).
Insulin resistance, 1-h plasma
glucose, and 2-h plasma glucose
Both 1-h plasma glucose and 2-h plasma
glucose values were inversely related to
insulin sensitivity (1-h plasma glucose
6.741.9mmol/lininsulin-sensitivein-
dividuals, 7.3  2.1 mmol/l in subjects
with intermediate insulin sensitivity, and
8.62.1mmol/lininsulin-resistantsub-
jects, P  0.001; 2-h plasma glucose
5.0  1.2, 5.5  1.3, and 6.4  1.5
mmol/l, respectively, P  0.001). Glu-
cose concentrations of insulin-resistant
participants during the OGTT were
higher than those of other participants at
all time points (P  0.0001, repeated-
measures ANOVA, time points, group,
and time per group), the greatest differ-
ence being at 1 h (7.2  2.1 vs. 8.6  2.1
mmol/l, corresponding to a difference of
25 mg/dl). In contrast, 2-h plasma glu-
cose values were 5.5  1.3 vs. 6.4  1.5
mmol/l (a difference of 17 mg/dl).
Insulin sensitivity, hepatic insulin ex-
traction, basal and total insulin secretion,
-cell glucose sensitivity, rate sensitivity,
and potentiation factor correlated signiﬁ-
cantly with both 1-h plasma glucose and
2-hplasmaglucose(supplementaryTable
1S, available in an online appendix at
http://care.diabetesjournals.org/cgi/
content/full/dc09-2261/DC1), although
higher r values were noted for 1-h plasma
glucose than for 2-h plasma glucose in
the correlations with total insulin secre-
tion, -cell glucose sensitivity, and rate
sensitivity.
Independent and signiﬁcant predic-
tors of insulin resistance determined by
stepwise logistic regression, using the
variables of sex, age, 1-h plasma glucose,
2-h plasma glucose, BMI, and waist cir-
cumference, were 1-h plasma glucose
(OR 1.10 [95% CI 1.01–1.20]), 2-h
plasma glucose (1.41 [1.24–1.60]), BMI
(1.23 [1.18–1.29]), and female sex (0.41
[0.29–0.57]).
Insulin secretion, 1-h plasma
glucose, and 2-h plasma glucose
Whetherconsideringtotalorbasalinsulin
secretion, we found that hypersecretors
had higher 1-h plasma glucose and 2-h
plasma glucose values (P  0.001 by
ANOVA for all Bonferroni pairwise com-
parisons) (Table 1), although no differ-
ence in 1-h plasma glucose or 2-h plasma
glucose was detected between hyposecre-
tors and participants with normal secre-
tion. No difference in 1-h plasma glucose
or 2-h plasma glucose was detected when
participants were categorized according
to insulin clearance (P  0.09) or hepatic
insulin extraction (P  0.2), respectively.
Insulin resistance and insulin
secretion in participants with NGT
categorized by IGT-based threshold
of 1-h plasma glucose
Mean 1-h plasma glucose in the 105 indi-
viduals with IGT was 10.11  1.67
mmol/l (upper and lower deciles 12.04
and 7.86 mmol/l). Receiver operating
characteristiccurveanalysisforsensitivity
and speciﬁcity of 1-h plasma glucose to
predict IGT provided an area of 0.86 
0.02 (P  0.001) with a glucose level of
8.95 mmol/l (sensitivity 77% and speci-
ﬁcity 80%), maximizing sensitivity and
speciﬁcity. When this 1-h plasma glucose
threshold was used to categorize individ-
ualswithNGT(Table2),222participants
had 1-h plasma glucose 8.95 mmol/l
and 878 participants with NGT had 1-h
plasma glucose 8.95 mmol/l.
Comparison of participants with
NGT, NGT with 1-h plasma
glucose >8.95 mmol/l, and IGT
ANOVA was signiﬁcant for all variables
considered except insulin clearance dur-
ing the EHC. Post hoc comparisons of
participants with NGT with 1-h plasma
glucose 8.95 mmol/l demonstrated sig-
niﬁcantly larger waist circumference
(90.6  12.3 vs. 84.3  11.9 cm), higher
BMI (26.2  3.9 vs. 24.9  3.8 kg/m
2),
lower ln(M/I) (4.7  0.5 vs. 4.9  0.5,
corresponding to 110 vs. 134 	mol  
min
1   kgFFM
1   nmol/l
1), higher fast-
ing glucose (5.2  0.5 vs. 4.9  0.5
mmol/l), and higher basal (82.9  31.7
vs. 68.9  27.5 pmol   min
1   m
2) and
total insulin secretion (47.9  13.9 vs.
37.8  12 nmol   m
2)( P  0.001 for all
comparisons) than their counterparts with
NGT with 1-h plasma glucose 8.95
mmol/l (Table 2). Moreover, they exhibited
lower glucose sensitivity (86.9  30.3 vs.
153.1  97.3 pmol   min
1   m
2   mmol/
l
1; P  0.001), lower rate sensitivity
(781.8561.7vs.1150.21431.5pmol 
m
2   mmol/l
1; P  0.001), lower poten-
tiation factor (1.9  1.0 vs. 2.2  1.6; P 
0.026), higher total cholesterol (5.04 
0.9 vs. 4.8  0.9 mmol/l; P  0.001),
lower HDL cholesterol (1.35  0.4 vs.
1.47  0.4 mmol/l; P  0.001), higher
LDLcholesterol(3.10.8vs.2.80.8
mmol/l; P  0.001), and higher triglyc-
erides (1.28  0.9 vs. 1  0.5 mmol/l;
P  0.001) (Fig. 1).
Post hoc comparison of subjects with
NGT and 1-h plasma glucose 8.95
mmol/l versus those with IGT revealed
no difference in age, waist circumfer-
ence, fasting glucose, hepatic insulin
extraction, -cell glucose sensitivity,
rate sensitivity, potentiation factor, to-
tal cholesterol, HDL cholesterol, LDL
cholesterol, and triglycerides. For sub-
jects with IGT, those with NGT with 1-h
plasmaglucose8.95mmol/lhadhigher
FFM (56.7  11.03 vs. 51.8  11.0 kg;
P  0.001), insulin sensitivity [4.7  0.5
vs. 4.5  0.5 log(	mol   min
1   kgFFM
1
 nmol/l
1);P0.001)inthepresenceof
lower basal (82.9  31.6 vs. 95.5  33.4
pmol   min
1   m
2; P  0.001) and total
insulin secretion (47.9  13.9 vs. 53 
17.8 nmol   m
2; P  0.002) (Fig. 1).
Sixty-eight (30.6%) of 222 partici-
pants with NGT with 1-h plasma glucose
8.95mmol/lwereinsulinresistantcom-
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pants with 1-h plasma glucose 8.95
mmol/l (P  0.001). The OR for insulin
resistance was 2.52 (95% CI% 1.8–3.5).
Moreover,intermsofbothbasalandtotal
insulin secretion, a higher percentage of
participants with 1-h plasma glucose
8.95 mmol/l were hypersecretors as de-
ﬁnedabove:(basal)95(42.8%)of222vs.
191 (21.75%) of 878 (P  0.001; OR 2.7
[1.8–3.7]); and (total) 82 (36.9%) of 222
vs.102(11.62%)of878(P0.001;4.46
[3.2–6.3]).
CONCLUSIONS — Our analysis of
cross-sectional data from the RISC study
suggests that increased 1-h plasma glu-
cose (8.95 mmol/l) on an OGTT iden-
tiﬁes a subgroup of individuals with
increased insulin resistance and -cell
dysfunction (reduced -cell rate sensitiv-
ity, glucose sensitivity, and potentiation
factor) (Fig. 1) who would otherwise be
classiﬁed as having NGT by current deﬁ-
nitions (4).
Not unexpectedly, these differences
in insulin sensitivity may relate to in-
creased visceral and total body fat. Thus,
participants with NGT with 1-h plasma
glucose 8.95 mmol/l do not differ from
individuals with IGT in waist circumfer-
ence, insulin clearance, hepatic insulin
extraction, -cell rate sensitivity, glucose
sensitivity, and potentiation factor. How-
ever, participants with NGT with 1-h
plasma glucose 8.95 mmol/l are more
insulin sensitive than those with IGT al-
beit they present already impaired dy-
namic -cell function.
Individuals with NGT but IGT-level
excursions of plasma glucose at 1-h dur-
ing the glucose challenge may therefore
represent an intermediate state of glucose
intolerance. It is known that insulin sen-
sitivityvariesoverasix-tosevenfoldrange
in individuals with NGT (10) as -cell
compensation can preserve NGT. Four
factors inﬂuence this dynamic relation-
ship: 1) -cell glucose sensitivity, i.e., the
ability of -cells to respond to changes in
plasmaglucoseconcentration;2)ratesen-
sitivity, i.e., the ability to respond to
changesintherateofvariationsofglucose
concentration; 3) potentiation, which
depends on glucose potentiation per se,
incretin potentiation and neural modula-
tion; and 4) the degree of insulin resis-
tance. In the spectrum from glucose
tolerance to intolerance, -cell glucose
sensitivity progressively decreases,
whereas insulin secretion classically ex-
hibits an inverted U-shape. Rate sensitiv-
ity is impaired in individuals with NGT
with high 1-h plasma glucose to the same
extent as in individuals with IGT.
A higher level of 1-h plasma glucose
mightrepresentasurrogatemarkerofim-
paired-cellfunction(-cellglucosesen-
sitivity and rate sensitivity) in individuals
Table 1—One-hour plasma glucose and 2-h plasma glucose after OGTT in subjects stratiﬁed according to parameters deriving from the
clamp and from the OGTT
Classiﬁcation %
1-h plasma
glucose P value
2-h plasma
glucose P value
Insulin clearance (l/min/m
2)
Low clearance (0.47) 15.5 7.82  2.22 0.096 5.9  1.41 0.003
Normal clearance (0.470–0.82) 72.9 7.48  2.14 5.67  1.42
High clearance (0.82) 11.6 7.34  2.54 5.37  1.53
Insulin sensitivity 
log(	mol   min
1   kgFFM
1   nmol/l
1)
Hypersensitivity 
ln(M/I) 5.53 6.4 6.74  1.90 0.001 5.01  1.17 0.001
Normal sensitivity 
4.47  ln(M/I)  5.53 72.9 7.27  2.15 5.51  1.35
Insulin resistance 
ln(M/I) 4.47 20.7 8.63  2.12 6.4  1.51
Total insulin secretion (nmol   m
2)
Low secretion (24.60) 9.1 6.15  1.90 0.001 4.87  1.22 0.001
Normal secretion (24.60–54.54) 71.8 7.3  2.05 5.57  1.36
High secretion (54.54) 19.1 8.98  2.20 6.41  1.50
Basal insulin secretion (pmol   min
1   m
2)
Low secretion (37.98) 6.6 6.78  1.94 0.001 5.18  1.21 0.001
Normal secretion (37.98–92.10) 65.1 7.20  2.04 5.51  1.38
High secretion (92.10) 28.3 8.41  2.37 6.14  1.49
Insulin extraction (adimensional)
Low extraction (0.44) 16.43 8.07  2.46 0.001 5.82  1.54 0.182
Normal extraction (0.44–0.76) 78.09 7.44  2.14 5.65  1.41
High extraction (0.76) 5.48 6.98  2.15 5.49  1.38
Glucose sensitivity (pmol   min
1   m
2   mmol/l
1)
Low sensitivity (54.76) 11.62 8.86  2.89 0.001 6.38  1.74 0.001
Normal sensitivity (54.76–247.37) 80.41 7.54  2.01 5.64  1.38
High sensitivity (247.37) 7.97 5.30  0.99 4.89  0.89
Rate sensitivity (pmol   m
2   mmol/l
1)
Low sensitivity (3.34  10
12) 8.30 6.51  1.91 0.001 5.31  1.28 0.001
Normal sensitivity (3.34  10
12–2,494.27) 81.83 7.83  2.18 5.79  1.42
High sensitivity (2,494.27) 9.88 5.75  1.52 4.96  1.39
Data are means  SD or % individuals within each group. P  0.001 from ANOVA. All Bonferroni comparisons were signiﬁcant except the comparisons between
participants with 1) normal and low basal insulin secretion for both 1-h plasma glucose and 2-h plasma glucose, 2) normal and high hepatic insulin extraction for
1-h plasma glucose, 3) low and high rate sensitivity for 2-h plasma glucose, 4) normal and low as well as normal and high insulin clearance for 2-h plasma glucose,
and 5) normal insulin sensitivity and hypersensitivity for 1-h plasma glucose.
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glucose >8.95 mmol/l (group 1), and participants with IGT (group 2)
Classiﬁcation n Value P value
P value for group comparison
0 vs. 1 1 vs. 2 0 vs. 2
Age (years)
NGT with 1-h plasma glucose 8.95 mmol/l 878 43.01  8.27
NGT with 1-h plasma glucose 8.95 mmol/l 222 45.39  8.26 0.001 0.001 NS 0.001
IGT 105 46.01  7.96
Waist (cm)
NGT with 1-h plasma glucose 8.95 mmol/l 863 84.28  11.88
NGT with 1-h plasma glucose 8.95 mmol/l 220 90.61  12.34 0.001 0.001 NS 0.001
IGT 105 91.38  13.47
BMI (kg/m
2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 24.86  3.77
NGT with 1-h plasma glucose 8.95 mmol/l 222 26.25  3.95 0.001 0.001 NS 0.001
IGT 105 27.27  4.39
Insulin sensitivity 
log(	mol   min
1   kgFFM
1   nmol/l
1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 4.93  0.45
NGT with 1-h plasma glucose 8.95 mmol/l 222 4.73  0.51 0.001 0.001 0.001 0.001
IGT 105 4.49  0.48
Fasting plasma glucose (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 878 4.94  0.49
NGT with 1-h plasma glucose 8.95 mmol/l 222 5.25  0.47 0.001 0.001 NS 0.001
IGT 105 5.17  0.48
Basal insulin secretion (pmol   min
1   m
2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 68.94  27.52
NGT with 1-h plasma glucose 8.95 mmol/l 222 82.87  31.66 0.001 0.001 0.001 0.001
IGT 105 95.52  33.42
Total insulin secretion (nmol   m
2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 37.79  12.00
NGT with 1-h plasma glucose 8.95 mmol/l 222 47.86  13.90 0.001 0.001 0.002 0.001
IGT 105 53.05  17.82
Insulin clearance (l/min/m
2)
NGT with 1-h plasma glucose 8.95 mmol/l 878 0.63  0.25
NGT with 1-h plasma glucose 8.95 mmol/l 222 0.62  0.18 NS
IGT 105 0.62  0.23
Insulin extraction
NGT with 1-h plasma glucose 8.95 mmol/l 878 0.59  0.24
NGT with 1-h plasma glucose 8.95 mmol/l 222 0.52  0.48 0.003 NS NS 0.003
IGT 105 0.37  1.90
Glucose sensitivity (pmol   min
1   m
2   mmol/l
1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 153.12  97.34
NGT with 1-h plasma glucose 8.95 mmol/l 222 86.88  30.28 0.001 0.001 NS 0.001
IGT 105 80.38  44.26
Rate sensitivity (pmol   m
2   mmol/l
1)
NGT with 1-h plasma glucose 8.95 mmol/l 878 1,150.22  1,431.50
NGT with 1-h plasma glucose 8.95 mmol/l 222 781.78  561.72 0.001 0.001 NS NS
IGT 105 987.14  859.81
Potentiation factor
NGT with 1-h plasma glucose 8.95 mmol/l 878 2.17  1.55
NGT with 1-h plasma glucose 8.95 mmol/l 222 1.89  1.04 0.001 0.026 NS 0.001
IGT 105 1.50  0.57
Total cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 874 4.75  0.85
NGT with 1-h plasma glucose 8.95 mmol/l 220 5.04  0.94 0.001 0.001 NS NS
IGT 104 4.92  0.84
(continued)
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are insulin resistant. In the RISC cohort,
according to this analysis, NGT partici-
pants with 1-h plasma glucose 8.95
mmol/l had an OR of 2.5 for insulin
resistance.
The concept that hyperglycemia
(even within the normal range of glucose
tolerance) may arise from an intrinsic
-cell defect in the presence of increased
insulin resistance has been reinforced in
recent years by a number of studies in
Table 2—Continued
Classiﬁcation n Value P value
P value for group comparison
0 vs. 1 1 vs. 2 0 vs. 2
HDL cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 875 1.47  0.38
NGT with 1-h plasma glucose 8.95 mmol/l 220 1.35  0.36 0.001 0.001 NS 0.001
IGT 104 1.33  0.35
LDL cholesterol (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 870 2.83  0.78
NGT with 1-h plasma glucose 8.95 mmol/l 213 3.10  0.83 0.001 0.001 NS NS
IGT 104 2.99  0.81
Triglycerides (mmol/l)
NGT with 1-h plasma glucose 8.95 mmol/l 875 0.99  0.52
NGT with 1-h plasma glucose 8.95 mmol/l 220 1.28  0.88 0.001 0.001 NS 0.001
IGT 104 1.32  0.64
Data are means  SD unless otherwise indicated. n represents the absolute frequency and varies according to missing data for each variable. P values are reported
for statistical signiﬁcance from ANOVA and Bonferroni post hoc comparisons.
Figure 1—Comparison of insulin sensitivity (A), -cell glucose sensitivity (B), rate sensitivity (C), potentiation factor (D), basal insulin secretion
(E), and total insulin secretion (F) among the following groups: NGT with 1-h plasma glucose 8.95 mmol/l (gray bars); NGT with 1-h plasma
glucose 8.95 mmol/l (hatched bars), and IGT individuals (white bars). Signiﬁcance is reported using the Bonferroni post hoc test.
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(3,13). However, these studies have fo-
cused on the association between dy-
namic parameters of -cell function and
2-h plasma glucose. Our study is unique
in that we have focused on 1-h plasma
glucose.
In clinical practice, neither IFG nor
IGT is considered a clinical entity but
rather both are risk categories for devel-
opment of type 2 diabetes and cardiovas-
cular disease. Glycemic thresholds are
basedonaconsensusinterpretationofev-
idence, with cutoff values representing
points at which risk is deemed excessive
(14,15). Nevertheless, studies have
shown that targeted treatment of IGT can
reduceprogressiontotype2diabetes,and
theriskofcardiovasculardiseaseorfuture
diabetes seems to be continuous across
the glucose range (16).
Thereareexamplesintheliteratureof
1-hplasmaglucosebeingpredictiveofthe
riskofmyocardialinfarction(17)andcor-
onary heart disease (18,19) in type 2 dia-
betes. One-hour plasma glucose was a
strong predictor of development of type 2
diabetes in a large cohort of 1,611 partic-
ipants without diabetes in the San Anto-
nio Heart Study (20,21). Furthermore,
1-h plasma glucose values improved the
accuracy of a model to predict develop-
ment of type 2 diabetes incorporating
components of the metabolic syndrome
(21), with a 1-h plasma glucose concen-
tration of 155 mg/dl (8.5 mmol/l) identi-
ﬁed to stratify three classes of risk. In this
study 16.7% of participants with NGT
with 1-h plasma glucose concentration
155 mg/dl developed type 2 diabetes
over a 7- to 8-year period, whereas those
with NGT and 1-h plasma glucose 155
mg/l, plus the metabolic syndrome, were
at much higher risk for the development
of diabetes, exceeding that of those with
IGT (21). One-hour plasma glucose was
also shown to correlate more strongly
with surrogate measures of hepatic and
muscle insulin resistance and -cell dys-
function than 2-h plasma glucose (20).
Analysis of cohort data from the San An-
tonio Heart and the Botnia studies (22)
demonstratedthat1-hplasmaglucoseisa
better predictor of future type 2 diabetes
than 2-h plasma glucose with a 13.1-fold
increased OR for developing the disease
in subjects with higher 1-h plasma glu-
cose (155 mg/dl).
These observations are consistent
with the results of the present analysis,
supporting the concept that the 1-h
plasma glucose concentration can iden-
tify participants with NGT according to
current deﬁnitions who have an adverse
metabolic proﬁle at an earlier stage. We
speculate that they too may beneﬁt from
lifestyle (and possibly pharmacological)
interventions analogous to the state of
IGT (16).
A limitation of the present study is
lack of longitudinal data. However, such
datawillbeavailablethroughongoingfol-
low-up of the RISC cohort. In contrast, a
major strength of our study is the consis-
tentmethodologyusedtoevaluateinsulin
sensitivity across centers in a large Euro-
pean population.
Insummary,ourdatasuggestthat1-h
plasma glucose may represent an index of
metabolic impairment useful in clinical
practice to identify individuals with more
severe insulin resistance and impaired
-cell glucose sensitivity and rate sensi-
tivity. These individuals might beneﬁt
from an intervention program (with diet,
exercise, and/or pharmacotherapy). Fu-
ture longitudinal studies are necessary to
evaluate the association between 1-h
plasma glucose and the risk of develop-
ment of type 2 diabetes and/or cardiovas-
cular disease.
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